2018’s M&A Frenzy Has Begun: Juno Therapeutics Inc (JUNO), Celgene Corporation (CELG)

Celgene Corporation (NASDAQ:CELG) announced this morning that it is acquiring Juno Therapeutics Inc (NASDAQ:JUNO) for $9 billion or $87/share (net of the ~10% it …

Juno Therapeutics Inc May Be the Ideal Takeout Target for a Large Pharma like Celgene: Jason McCarthy

In reaction to acquisition buzz in the market’s grapevine, Maxim’s Jason McCarthy is out boosting his price target on Juno stock.

Juno Therapeutics Inc (JUNO) Spikes on Rumors of Celgene Takeover; Analysts Dive in

Healthcare analysts share thoughts on a potential acquisition of Juno Therapeutics.

Juno Therapeutics Inc (JUNO) to Make Key Presentations; Shares Soar

Juno Therapeutics Inc (NASDAQ:JUNO) shares gained 9% after the company said it will present updated clinical and preclinical results from the company and …

Company Update (NASDAQ:JUNO): Juno Therapeutics Inc Opens New Headquarters and Research Center

Juno Therapeutics Inc (NASDAQ:JUNO) unveiled its new headquarters and research facility, located in the heart of South Lake Union in Seattle. The new headquarters brings together Juno’s Seattle employees …

Juno Therapeutics Inc (JUNO) Looks Well Positioned in Light of KITE Takeout: Top Analyst

David Nierengarten Re-evaluates JUNO; Upgrades Shares to Outperform

Biotech World’s Big M&A Frenzy: Kite Pharma Inc (KITE), Gilead Sciences, Inc. (GILD), Juno Therapeutics Inc (JUNO)

How Has a Deal Between Kite and Gilead Likewise Sent Juno Shares Jumping?

BTIG Shares Two Cents on Juno Therapeutics Inc (JUNO) Following ASCO Abstract

In a research report published Monday, BTIG analyst Dane Leone reiterated a Neutral rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), after the …

Juno Therapeutics Inc (JUNO) Presents Updated TRANSCEND NHL 001 Trial Data at ASCO

Juno Therapeutics Inc (NASDAQ:JUNO) announced updated data from the TRANSCEND trial of JCAR017 in relapsed and refractory (r/r) aggressive B cell non-Hodgkin lymphoma …

J.P. Morgan Clips Price Target on Juno Therapeutics Inc (JUNO) Following Termination of JCAR015 Program

Juno Therapeutics Inc (NASDAQ:JUNO) shares are dropping 7% following the biotech firm’s official termination of their JCAR015 program for the treatment of patients …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts